Abstracts tagged "ankylosing spondylitis (AS) and treatment"

Abstract Number: 896 • 2018 ACR/ARHP Annual Meeting
Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population
Jing Liu¹, Weilin Pu¹, Qi Zhu², He Fan¹, Wei Wan³, Hejian Zou⁴, Xiaodong Zhou⁵, John D. Reveille⁶, Dongyi He² and Jiucun Wang¹, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ³Division of Rheumatology, Changhai Hospital, Shanghai, China, ⁴Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ⁵Internal Medicine-Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: TNF blockers, have been widely used in immune-mediated diseases and many genetic variations predicting treatment response have been described. We applied previously published genetic…
Abstract Number: 910 • 2018 ACR/ARHP Annual Meeting
In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016
Jessica Walsh¹, Theresa Hunter², Rebecca Bolce², David Sandoval Calderon² and Krista Schroeder², ¹University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: This study aimed to analyze the prevalence rates and treatment patterns of male and female ankylosing spondylitis (AS) patients in the United States (US)…
Abstract Number: 2607 • 2018 ACR/ARHP Annual Meeting
Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
Gi Bum Bae¹, Seungwoo Han², Jong Wan Kang², Jung Su Eun², Sang Jin Lee¹ and Eon Jeong Nam², ¹Internal medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South), ²Internal Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South)
Background/Purpose: Limited spinal mobility is a cardinal sign of ankylosing spondylitis (AS) and shows a close relationship with functional disability which leads to high individual…
Abstract Number: 579 • 2017 ACR/ARHP Annual Meeting
Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis
Klára Prajzlerová¹, Veronika Hruskova¹, Martin Komarc², Šárka Forejtová¹, Karel Pavelka³, Jiri Vencovsky³, Ladislav Senolt³ and Maria Filkova¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Department of Anthropometrics and Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: The altered expression of miRNAs contributes to the pathophysiology of inflammatory conditions. In addition, circulating miRNAs may serve as promising therapeutic and prognostic biomarkers.…
Abstract Number: 1524 • 2017 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab Among Biologic-NaïVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States
Kurt R. Oelke¹, Rahul Garg², Yunfeng Li³, Xing Liu⁴, Huanxue Zhou⁴ and Yujin Park³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴KMK Consulting, Inc, Morristown, NJ
Background/Purpose: Secukinumab is a fully human anti–interleukin-17A monoclonal antibody approved for the treatment of patients with moderate to severe ankylosing spondylitis (AS). A limited number…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].